Figure 5.

PBMT enhances SIRT1 activity via the cAMP/PKA pathway. (a) SIRT1 activity assay kit was used to detect SIRT1 deacetylase activity after treatment with PBMT in the presence of API‐2 (2 μM), PD98059 (1 μM), Gӧ6983 (20 μM), and H‐89 (20 μM) in neurons. (b) SIRT1 deacetylase activity was detected after the indicated treatments in SH‐SY5Y cells. (c) Representative Western blot assay for detecting the dose‐dependent effects of PBMT on p‐PKA in APP/PS1 neurons. (d) Representative Western blot assay for detecting the levels of p‐PKA and p‐SIRT1 after treatment with H‐89 in SH‐SY5Y‐APPswe cells. (e) Representative Western blot assay for detecting the levels of SIRT1 after indicated treatments in cytoplasm (Cyto) and nuclear (Nuc) lysates of SH‐SY5Y‐APPswe cells, respectively. (f) Representative immunofluorescent images of SIRT1 (green) in SH‐SY5Y‐APPswe cells under the indicated treatments. Staining with DAPI (blue) to visualize nucleus. All the data are reported as mean ± SEM of four independent experiments. *p < 0.05 and **p < 0.01 versus the control group; #p < 0.05 and ##p < 0.01 versus the indicated group